메드팩토

235980KOSDAQ

53.3 / 100

Reference Date: 2026-09-09

Financial Score17.5 / 40

News Sentiment19.8 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly up 3.1% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Medfact is a biotech company established in 2013, specializing in the development of innovative drugs for refractory cancers using advanced genomic analysis technology. Its flagship product, Vactosertib, targets the TGF-β1 signaling pathway to modulate the tumor microenvironment and enhance the efficacy of existing cancer treatments when used in combination. The company is currently conducting clinical trials for various cancers, including colorectal, pancreatic, and osteosarcoma.

Number of Employees

54people

Average Salary

57.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

2.13Industry Average 1.201.0Point

1.8x industry avg (risky)

ROE

-24.70Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

2.86Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20254.5 / 10 points

Revenue Growth Rate

1.5 / 3

Operating Profit Growth Rate

3.0 / 3

Avg ▲29.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -41.5% (improving, 3yr)

Detailed News Sentiment

6 totalPositive 5Neutral 1Negative 0Average Sentiment Score 79.2

Positive
투자 1년 만에 4배 회수…'PE' 본능 살려 수익 극대화
메드팩토의 투자 회수율이 1년 만에 4배 증가하여 수익 극대화에 성공했다.
Positive
모더나·MSD 암 백신 3상에 수혜주 찾기 분주…삼양바이오팜 ‘상한가....
메드팩토의 상한가는 모더나와 MSD의 mRNA 암 백신 관련 긍정적 시장 동향에 따른 수혜로 분석됨.
Neutral
모더나가 띄운 '암치료 백신'…K-바이오도 '잰걸음'
국내 제약바이오 기업들은 글로벌 협력 사례를 참고하며 암백신 개발에 대한 연구를 지속하고 있으나, 직접적인 영향은 제한적.

Detailed Momentum

52-week position1.0Point

Near 52w low (10%, downtrend)

Current 2,855Won52-week high 8,05052-week low 2,240

1-month return4.0Point

1m +3.07% (slight rise)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral반기보고서 (2026.06)2026-08-13